The Quantellect read.As of Nov 19, 2026, 12 active firms cover ResMed Inc: 4 rate it Buy or better, 8 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $215.00 to $275.00, so the covering firms are broadly aligned. The average target of $240.82 sits 1% below the current $242.56. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $3.06 next quarter toward $13.23 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Neutral
Strong Buy00%
Buy433%
Neutral867%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$240.82
-0.7% downside
Average target across 11 active firms as of Nov 19, 2026 vs $242.56 current
Highest Target$275.00
Average Target$240.82
Lowest Target$215.00
Detailed analyst forecasts for RMD
Showing 1–13 of 13 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 4 of 12 active firms rate RMD a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RMD EPS & revenue forecast
EPS · NEXT QUARTER
$3.06
Range $3.02 – $3.10 · 13 analysts · +7% YoY
Next period, 13 analysts expect ResMed Inc to earn $3.06 a share (range $3.02 – $3.10), versus $2.86 a year earlier. Full-year consensus is $12.14, growing to $13.23 the year after.
REVENUE · NEXT QUARTER
$1.5B
Range $1.4B – $1.5B · 13 analysts · +2% YoY
Revenue is expected to reach $1.5B (range $1.4B – $1.5B), +1.8% year-over-year. Full-year consensus is $5.8B, rising to $6.2B next year.
Top analysts covering ResMed Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RMD.
#1
Anthony Petrone
Mizuho · Rank #121
Buy
$235.00-3.1% to target
Overall win rate
45%
+ Follow
#2
Jonathan Block
Stifel · Rank #294
Neutral
$235.00-3.1% to target
Overall win rate
36%
+ Follow
#3
Justin Patterson
Keybanc · Rank #505
Buy
$266.00+9.7% to target
Overall win rate
30%
+ Follow
#4
CW
Craig Wong-Pan
RBC Capital
Buy
$288.00+18.7% to target
Coverage
—
+ Follow
#5
LS
Laura Sutcliffe
Citigroup
Neutral
$270.00+11.3% to target
Coverage
—
+ Follow
RMD stock forecast FAQ
What is RMD's average 12-month price target?+
The 11 active firms with a live target average $240.82 for ResMed Inc over the next 12 months, ranging from a $275.00 high to a $215.00 low, as of Nov 19, 2026.
Is RMD stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 12 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 8 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RMD?+
The Street-high target is $275.00 (Baird), and the Street-low is $215.00 (Wells Fargo). The average of all 11 active-firm targets is $240.82.
How many active Wall Street firms cover RMD?+
12 active firms have a recognized rating on ResMed Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RMD?+
Among analysts who currently cover RMD, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #121). Their current call is Buy with a $235.00 target.
What is ResMed Inc's projected EPS for next quarter?+
The consensus estimate is $3.06 per share (range $3.02 – $3.10) across 13 analysts. Full-year EPS is projected at $12.14, rising to $13.23 the following year.
How much revenue is ResMed Inc expected to report next quarter?+
Consensus revenue is $1.5B (range $1.4B – $1.5B). Full-year revenue is projected at $5.8B, growing to $6.2B next year.
Have analysts been upgrading or downgrading RMD lately?+
As of Nov 19, 2026, 4 of 12 active firms rate RMD a Buy (8 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.